Alzamend Neuro (ALZN) Non-Current Deferred Tax Liability (2024 - 2026)
Alzamend Neuro's (ALZN) quarterly Non-Current Deferred Tax Liability came in at $14114.0 in Q2 2026, down 40.82% year-over-year from $23848.0 in Q2 2025, and down 40.82% quarter-over-quarter from $23848.0 in Q2 2025.
Analysis
Alzamend Neuro (ALZN) Non-Current Deferred Tax Liability (2024 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Non-Current Deferred Tax Liability across 3 years of filings, most recently posting $14114.0 for Q2 2026.
- In Q2 2026, Non-Current Deferred Tax Liability fell 40.82% year-over-year to $14114.0; the TTM figure through Apr 2026 stood at $14114.0 (down 40.82% YoY), while the FY2026 annual figure was $14114.0, down 40.82% from the prior year.
- Non-Current Deferred Tax Liability came in at $14114.0 for Q2 2026 at Alzamend Neuro, down from $23848.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $32400.0 in Q2 2024 to a low of $14114.0 in Q2 2026.
- Average Non-Current Deferred Tax Liability over 3 years is $23454.0, with a median of $23848.0 recorded in 2025.
- Year-over-year, Non-Current Deferred Tax Liability slipped 26.4% in 2025 and tumbled 40.82% in 2026.
- Over 3 years, Non-Current Deferred Tax Liability stood at $32400.0 in 2024, then fell by 26.4% to $23848.0 in 2025, then slumped by 40.82% to $14114.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $14114.0 in Q2 2026, $23848.0 in Q2 2025, and $32400.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.51 Bn | 192.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.28 Bn | 176.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.06 Bn | 123.21 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.62 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.71 Bn | 55.52 Bn | 1.37 Bn |
| 6 | Moderna | 53.60 Bn | 48.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.79 Bn | 30.50 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.11 Bn | 29.11 Bn | 1.16 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 14,114.00 |
| Apr 30, 2025 | 23,848.00 |
| Apr 30, 2024 | 32,400.00 |